717 related articles for article (PubMed ID: 23215753)
1. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
13. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
14. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
16. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
17. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
18. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]